{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:38:18Z","timestamp":1790246298000,"version":"4.1.0"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"Supplement_4","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000313","name":"the British Society for Antimicrobial Chemotherapy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001316","name":"Abbott","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020948","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021742","name":"Aventis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021742","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009930","name":"Basilea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009930","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019189","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019189","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cempra"},{"DOI":"10.13039\/100011888","name":"Cerexa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011888","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cubist"},{"name":"GeneSoft"},{"DOI":"10.13039\/501100002066","name":"GSK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004331","name":"Johnson & Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004634","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004634","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016956","name":"Melinta","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016956","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019428","name":"Nabriva","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020604","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020604","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Oscient"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Replidyne"},{"name":"Rib-X"},{"DOI":"10.13039\/100013993","name":"Theravance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013993","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004342","name":"Wyeth","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004342","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The BSAC Bacteraemia Resistance Surveillance Programme collected isolates from UK and Irish hospitals for central testing. Concurrent UKHSA surveillance collected English hospitals\u2019 own susceptibility data. Results were reviewed and compared.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The BSAC surveillance collected fixed quotas of isolates per site annually from 2001 to 2019. MIC testing was by BSAC agar dilution. Resistance mechanisms were investigated by synergy tests, interpretive reading and PCR. The UKHSA seeks data on all bacteraemia isolates in England.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>For Escherichia coli, which now causes &amp;gt;30% of all bacteraemias, there were marked early (2002\u201306) rises in resistance to cephalosporins, fluoroquinolones and gentamicin, followed by small falls, stabilization, then from around 2015, very slow rises, with similar patterns seen for Klebsiella pneumoniae. Most cephalosporin resistance in these two species involved ESBLs, principally CTX-M types. Both species had frequent co-amoxiclav resistance. Cephalosporin resistance\u2014mostly AmpC-mediated\u2014declined in Enterobacter and Serratia spp., as did fluoroquinolone resistance, likely reflecting reduced use and selection pressure. Proteeae showed few changes; increasing dominance of Proteus mirabilis in the BSAC collection was not confirmed by the UKHSA dataset. Resistance in Pseudomonas aeruginosa was uncommon and showed little temporal change in either dataset. Carbapenemases remained extremely rare in all species. Newer and developmental agents covered many resistance types, but none covered all types.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Except for early rises of cephalosporin, fluoroquinolone and gentamicin resistance in E. coli and K. pneumoniae, there was little evidence for rising resistance and some evidence of declining resistance, notably in species where it predominantly involves AmpC derepression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf250","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T07:20:20Z","timestamp":1751872820000},"page":"iv36-iv48","source":"Crossref","is-referenced-by-count":7,"title":["Antimicrobial resistance among Gram-negative agents of bacteraemia in the UK and Ireland: trends from 2001 to 2019"],"prefix":"10.1093","volume":"80","author":[{"given":"Rosy","family":"Reynolds","sequence":"first","affiliation":[{"name":"Population Health Sciences, University of Bristol , Bristol BS8 2PS ,","place":["UK"]},{"name":"British Society for Antimicrobial Chemotherapy , 53 Regent Place, Birmingham B1 3NJ ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3908-8332","authenticated-orcid":false,"given":"Shazad","family":"Mushtaq","sequence":"additional","affiliation":[{"name":"Antimicrobial Resistance and Healthcare Associated Infections Reference Unit, UK Health Security Agency , Colindale, London NW9 5EQ ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2838-6833","authenticated-orcid":false,"given":"Russell","family":"Hope","sequence":"additional","affiliation":[{"name":"Antimicrobial Resistance and Healthcare Associated Infections Division, UK Health Security Agency , Colindale, London NW9 5EQ ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyne","family":"Horner","sequence":"additional","affiliation":[{"name":"British Society for Antimicrobial Chemotherapy , 53 Regent Place, Birmingham B1 3NJ ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Adkin","sequence":"additional","affiliation":[{"name":"Antimicrobial Resistance and Healthcare Associated Infections Reference Unit, UK Health Security Agency , Colindale, London NW9 5EQ ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiysha","family":"Chaudhry","sequence":"additional","affiliation":[{"name":"Antimicrobial Resistance and Healthcare Associated Infections Reference Unit, UK Health Security Agency , Colindale, London NW9 5EQ ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olisaeloka","family":"Nsonwu","sequence":"additional","affiliation":[{"name":"Antimicrobial Resistance and Healthcare Associated Infections Division, UK Health Security Agency , Colindale, London NW9 5EQ ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Allen","sequence":"additional","affiliation":[{"name":"British Society for Antimicrobial Chemotherapy , 53 Regent Place, Birmingham B1 3NJ ,","place":["UK"]},{"name":"Medical Affairs, MSD (UK) Limited , 120 Moorgate, London EC2M 6UR ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5586-7256","authenticated-orcid":false,"given":"Christopher","family":"Longshaw","sequence":"additional","affiliation":[{"name":"British Society for Antimicrobial Chemotherapy , 53 Regent Place, Birmingham B1 3NJ ,","place":["UK"]},{"name":"Scientific Affairs, Shionogi B.V. , Fifty Paddington, 50 Eastbourne Terrace, Paddington W2 6LG ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J","family":"Parcell","sequence":"additional","affiliation":[{"name":"Division of Population Health and Genomics, School of Medicine, University of Dundee, Ninewells Hospital and Medical School , Dundee DD1 9SY ,","place":["UK"]},{"name":"Department of Medical Microbiology, Ninewells Hospital and Medical School , Dundee DD1 9SY ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M","family":"Livermore","sequence":"additional","affiliation":[{"name":"Antimicrobial Resistance and Healthcare Associated Infections Reference Unit, UK Health Security Agency , Colindale, London NW9 5EQ ,","place":["UK"]},{"name":"Norwich Medical School, University of East Anglia , Norwich NR4 7TJ ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"2025102706022230300_dkaf250-B1","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1128\/CMR.2.4.329","article-title":"Clinical implications of positive blood cultures","volume":"2","author":"Bryan","year":"1989","journal-title":"Clin Microbiol Rev"},{"key":"2025102706022230300_dkaf250-B2","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/j.1469-0691.2010.03262.x","article-title":"Trends among pathogens reported as causing bacteraemia in England, 2004\u20132008","volume":"17","author":"Wilson","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"2025102706022230300_dkaf250-B3"},{"key":"2025102706022230300_dkaf250-B4","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1093\/jac\/dkab440","article-title":"Exploring temporal trends and risk factors for resistance in Escherichia coli-causing bacteraemia in England between 2013 and 2018: an ecological study","volume":"77","author":"Aliabadi","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2025102706022230300_dkaf250-B5","doi-asserted-by":"publisher","first-page":"e0120523","DOI":"10.1128\/mbio.01205-23","article-title":"The Gram-negative permeability barrier: tipping the balance of the in and the out","volume":"14","author":"Maher","year":"2023","journal-title":"mBio"},{"key":"2025102706022230300_dkaf250-B6","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1128\/CMR.00036-08","article-title":"Ampc","volume":"22","author":"Jacoby","year":"2009","journal-title":"Clin Microbiol Rev"},{"key":"2025102706022230300_dkaf250-B7","article-title":"European Antimicrobial Resistance Surveillance Network (EARS-net)","author":"Anon","journal-title":"Eur Cent Dis Prev Control"},{"key":"2025102706022230300_dkaf250-B8","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3389\/fmicb.2020.00271","article-title":"Global evolution of pathogenic bacteria with extensive use of fluoroquinolone agents","volume":"11","author":"Fuzi","year":"2020","journal-title":"Front Microbiol"},{"key":"2025102706022230300_dkaf250-B9","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1128\/CMR.00125-13","article-title":"Escherichia coli ST131, an intriguing clonal group","volume":"27","author":"Nicolas-Chanoine","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"2025102706022230300_dkaf250-B10","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1093\/jac\/dkl483","article-title":"CTX-M: changing the face of ESBLs in Europe","volume":"59","author":"Livermore","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"2025102706022230300_dkaf250-B11","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1080\/21505594.2016.1222343","article-title":"The global epidemiology of carbapenemase-producing Enterobacteriaceae","volume":"8","author":"van Duin","year":"2017","journal-title":"Virulence"},{"issue":"(Suppl 4)","key":"2025102706022230300_dkaf250-B12","doi-asserted-by":"crossref","first-page":"iv7","DOI":"10.1093\/jac\/dkaf248","article-title":"The British Society for Antimicrobial Chemotherapy Resistance Surveillance Project: methods and limitations","volume":"80","author":"Allen","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"2025102706022230300_dkaf250-B13","author":"Bischoff"},{"key":"2025102706022230300_dkaf250-B14","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1093\/jac\/dkab483","article-title":"Impact of changed co-amoxiclav susceptibility testing formats on apparent resistance rates for bloodstream Escherichia coli in a long-term surveillance","volume":"77","author":"Reynolds","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2025102706022230300_dkaf250-B15","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1128\/CMR.8.4.557","article-title":"\u03b2-Lactamases in laboratory and clinical resistance","volume":"8","author":"Livermore","year":"1995","journal-title":"Clin Microbiol Rev"},{"key":"2025102706022230300_dkaf250-B16","doi-asserted-by":"publisher","first-page":"ii41","DOI":"10.1093\/jac\/dkn351","article-title":"Non-susceptibility trends among Enterobacteriaceae from bacteraemias in the UK and Ireland, 2001\u201306","volume":"62","author":"Livermore","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"2025102706022230300_dkaf250-B17","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1093\/jac\/dkq161","article-title":"Activity of chequerboard combinations of ceftaroline and NXL104 versus \u03b2-lactamase-producing Enterobacteriaceae","volume":"65","author":"Mushtaq","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2025102706022230300_dkaf250-B18","doi-asserted-by":"publisher","first-page":"e00002","DOI":"10.1128\/CMR.00002-19","article-title":"Enterobacter spp.: update on taxonomy, clinical aspects, and emerging antimicrobial resistance","volume":"32","author":"Davin-Regli","year":"2019","journal-title":"Clin Microbiol Rev"},{"key":"2025102706022230300_dkaf250-B19","doi-asserted-by":"publisher","first-page":"473","DOI":"10.3201\/eid0805.010204","article-title":"Trends in fluoroquinolone (ciprofloxacin) resistance in Enterobacteriaceae from bacteremias, England and Wales, 1990\u20131999","volume":"8","author":"Livermore","year":"2002","journal-title":"Emerg Infect Dis"},{"key":"2025102706022230300_dkaf250-B20","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1093\/jac\/dkaa201","article-title":"Inherent colistin resistance in genogroups of the Enterobacter cloacae complex: epidemiological, genetic and biochemical analysis from the BSAC Resistance Surveillance Programme","volume":"75","author":"Mushtaq","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2025102706022230300_dkaf250-B21","doi-asserted-by":"publisher","first-page":"126289","DOI":"10.1016\/j.syapm.2021.126289","article-title":"Past, present and future of the boundaries of the Pseudomonas genus: proposal of Stutzerimonas gen","volume":"45","author":"Lalucat","year":"2022","journal-title":"Nov. Syst Appl Microbiol"},{"key":"2025102706022230300_dkaf250-B22","author":"Anon"},{"key":"2025102706022230300_dkaf250-B23","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/S1473-3099(19)30273-7","article-title":"Extended-spectrum \u03b2-lactamase-producing Escherichia coli in human-derived and foodchain-derived samples from England, Wales, and Scotland: an epidemiological surveillance and typing study","volume":"19","author":"Day","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2025102706022230300_dkaf250-B24","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1093\/jac\/dki239","article-title":"CTX-M: changing the face of ESBLs in the UK","volume":"56","author":"Livermore","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"2025102706022230300_dkaf250-B25","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1093\/jac\/dkt212","article-title":"Declining cephalosporin and fluoroquinolone non-susceptibility among bloodstream Enterobacteriaceae from the UK: links to prescribing change?","volume":"68","author":"Livermore","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2025102706022230300_dkaf250-B26","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1093\/jac\/47.6.789","article-title":"Antimicrobial susceptibility of Pseudomonas aeruginosa: results of a UK survey and evaluation of the British Society for Antimicrobial Chemotherapy disc susceptibility test","volume":"47","author":"Henwood","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"2025102706022230300_dkaf250-B27","author":"Anon"},{"key":"2025102706022230300_dkaf250-B28","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/S1473-3099(16)30514-X","article-title":"Effects of control interventions on Clostridium difficile infection in England: an observational study","volume":"17","author":"Dingle","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2025102706022230300_dkaf250-B29","doi-asserted-by":"publisher","first-page":"e3842","DOI":"10.1093\/cid\/ciaa1479","article-title":"Association between minimum inhibitory concentration, \u03b2-lactamase genes and mortality for patients treated with piperacillin\/tazobactam or meropenem from the MERINO study","volume":"73","author":"Henderson","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025102706022230300_dkaf250-B30","author":"Anon"},{"key":"2025102706022230300_dkaf250-B31","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.chest.2020.03.087","article-title":"A systematic review of the effect of delayed appropriate antibiotic treatment on the outcomes of patients with severe bacterial infections","volume":"158","author":"Zasowski","year":"2020","journal-title":"Chest"},{"key":"2025102706022230300_dkaf250-B32","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1093\/jac\/dkz548","article-title":"The EUCAST rapid disc diffusion method for antimicrobial susceptibility testing directly from positive blood culture bottles","volume":"75","author":"Jonasson","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2025102706022230300_dkaf250-B33","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.2217\/fmb-2020-0177","article-title":"Accelerate Pheno\u2122 blood culture detection system: a literature review","volume":"15","author":"Cenci","year":"2020","journal-title":"Future Microbiol"},{"key":"2025102706022230300_dkaf250-B34","doi-asserted-by":"publisher","first-page":"859935","DOI":"10.3389\/fcimb.2022.859935","article-title":"Diagnosis and management of bloodstream infections with rapid, multiplexed molecular assays","volume":"12","author":"Dunbar","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"2025102706022230300_dkaf250-B35","doi-asserted-by":"publisher","first-page":"e00231-21","DOI":"10.1128\/jcm.00231-21","article-title":"Direct-from-blood detection of pathogens: a review of technology and challenges","volume":"61","author":"Samuel","year":"2023","journal-title":"J Clin Microbiol"},{"key":"2025102706022230300_dkaf250-B36","doi-asserted-by":"publisher","first-page":"i13","DOI":"10.1093\/jac\/dkae282","article-title":"Evaluating the impact of rapid antimicrobial susceptibility testing for bloodstream infections: a review of actionability, antibiotic use and patient outcome metrics","volume":"79","author":"MacVane","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2025102706022230300_dkaf250-B37","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1093\/jac\/dkx136","article-title":"Activity of ceftolozane\/tazobactam against surveillance and \u2018problem\u2019 Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles","volume":"72","author":"Livermore","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2025102706022230300_dkaf250-B38","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1093\/jac\/dkz133","article-title":"Potentiation of imipenem by relebactam for Pseudomonas aeruginosa from bacteraemia and respiratory infections","volume":"74","author":"Horner","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2025102706022230300_dkaf250-B39","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1093\/jac\/dkm150","article-title":"In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes","volume":"60","author":"Mushtaq","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"2025102706022230300_dkaf250-B40","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1093\/cid\/ciab1013","article-title":"Infectious Diseases Society of America guidance on the treatment of AmpC \u03b2-lactamase-producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections","volume":"74","author":"Tamma","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2025102706022230300_dkaf250-B41","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ijmmb.2022.05.010","article-title":"Prevalence of faecal carriage of carbapenemase producing Enterobacteriaceae in healthy Indian subjects from the community","volume":"40","author":"Arum","year":"2022","journal-title":"Indian J Med Microbiol"},{"key":"2025102706022230300_dkaf250-B42","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1093\/jac\/dku568","article-title":"Characterization of Escherichia coli NDM isolates with decreased susceptibility to aztreonam\/avibactam: role of a novel insertion in PBP3","volume":"70","author":"Alm","year":"2015","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/Supplement_4\/iv36\/64943744\/dkaf250.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/Supplement_4\/iv36\/64943744\/dkaf250.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:02:35Z","timestamp":1761559355000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/Supplement_4\/iv36\/8301269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":42,"journal-issue":{"issue":"Supplement_4","published-online":{"date-parts":[[2025,10,27]]},"published-print":{"date-parts":[[2025,10,27]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf250","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,10]]}}}